Mechanisms of resistance to trastuzumab include HER2 receptor downregulation due to selection pressure, with evidence that 35% of HER2-positive oesophago-gastric cancer patients treated with trastuzumab lose HER2 positivity (25, 26). The gene discussed is ERBB2; the disease is gastric cancer.